Literature DB >> 32292884

Important Steps to Control COVID-19/SARS-CoV-2 Infection.

Sudipto Chatterjee1.   

Abstract

Elderly patients are having high mortality rates from COVID-19/SARS-CoV-2 infection compared to younger patients. The SARS-CoV-2 virus uses the ACE2 receptor as the entry point to the host cells. ARBs/ACEIs which are widely used in elderly patients, have been found to be associated with overexpression of ACE2.To decrease the severity of COVID-19 infection, ARB/ACEI should be switched to another class drug not known to cause a rise in ACE2 until the COVID-19 infection subsides. Specific human immunoglobulin can be tried for COVID-19 patients with critical conditions under supervision. © Springer Nature Switzerland AG 2020.

Entities:  

Keywords:  ACE2; ACEI; ARB; COVID-19; SARS-CoV-2

Year:  2020        PMID: 32292884      PMCID: PMC7140724          DOI: 10.1007/s42399-020-00271-7

Source DB:  PubMed          Journal:  SN Compr Clin Med        ISSN: 2523-8973


Introduction

On 11 March 2020, the WHO informed that COVID-19/SARS-CoV-2 can be characterized as a pandemic. Hoffmann et al. found that SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) for host cell entry [1]. Elderly people are found to be more susceptible to this infection [2]. This indicates a possible link in elderly patients of increased ACE2 levels to some preexisting comorbid conditions. Zhang et al. found that the common comorbid conditions associated with COVID-19/SARS-CoV-2 were hypertension and diabetes mellitus [3]. Earlier studies by Wang et al. and Furuhashi et al. have found that angiotensin II receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI) have been associated with overexpression of ACE2. This points towards a possible link between the severity of COVID-19 and use of ARB and ACEI [4, 5].

Discussion

My hypothesis proposes that a decrease in ACE levels can cause an increase in ACE2 expression. Studies by Wang et al. and Furuhashi et al. support this hypothesis. Wang et al. had found that use of ACEI is associated with overexpression of ACE2 [4]. Furuhashi et al. had found that ARBs are also associated with overexpression of ACE2 [5]. ARB and ACEI are widely used as one of the first-line drugs in hypertensive diabetic patients, diabetic nephropathy, and congestive cardiac failure, etc. These are very commonly witnessed comorbidities associated with many elderly patients. Hoffmann et al. found that SARS-CoV-2 uses the ACE2 as a receptor to enter the host cell, and the presence of overexpression of ACE2 can lead to a more severe form of COVID-19 infection [1]. This might be a possible explanation of why elderly patients with hypertension and diabetes are more affected by SARS-CoV-2 and why mortality rates are higher among them [6]. Many patients are also recovering from the current COVID-19 pandemic. The collection of specific human immunoglobulin from them and using the same for critically ill patients under strict supervision can be a life-saving measure. Earlier, Cheng et al. had found promising results using convalescent plasma therapy in SARS patients in Hong Kong [7]. My hypothesis is specific human immunoglobulin may be used as a standard protocol of therapy for any unknown viral pandemic.

Conclusion

In conclusion, the following steps need to be taken urgently to slow down and reduce the severity of this ongoing COVID-19 pandemic: Social distancing is the most important measure. Personal hygiene should be strictly maintained. Try to avoid contact with the mouth or mucous membrane with unclean hands. Patients suffering from COVID-19 infection who are also receiving ARB or ACEI should be switched to another class of drug not known to cause a rise in ACE2 until the COVID-19/SARS-CoV-2 infection subsides. This should only happen following careful consideration of all possible complications resulting from a temporary change in drug. Specific immunoglobulin from cured patients of COVID-19 should be collected and, under strict supervision, used for critically ill COVID-19-infected patients. In future, this may be considered as a standard therapy protocol for the treatment of any unkown viral pandemic.
  7 in total

1.  Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.

Authors:  Jin-Jin Zhang; Xiang Dong; Yi-Yuan Cao; Ya-Dong Yuan; Yi-Bin Yang; You-Qin Yan; Cezmi A Akdis; Ya-Dong Gao
Journal:  Allergy       Date:  2020-02-27       Impact factor: 13.146

2.  Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.

Authors:  Masato Furuhashi; Norihito Moniwa; Tomohiro Mita; Takahiro Fuseya; Shutaro Ishimura; Kohei Ohno; Satoru Shibata; Marenao Tanaka; Yuki Watanabe; Hiroshi Akasaka; Hirofumi Ohnishi; Hideaki Yoshida; Hideki Takizawa; Shigeyuki Saitoh; Nobuyuki Ura; Kazuaki Shimamoto; Tetsuji Miura
Journal:  Am J Hypertens       Date:  2014-05-18       Impact factor: 2.689

3.  Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy.

Authors:  G Wang; F M-M Lai; K-B Lai; K-M Chow; C-H B Kwan; K-T P Li; C-C Szeto
Journal:  Diabetologia       Date:  2008-04-04       Impact factor: 10.122

4.  Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China.

Authors:  Rossella Porcheddu; Caterina Serra; David Kelvin; Nikki Kelvin; Salvatore Rubino
Journal:  J Infect Dev Ctries       Date:  2020-02-29       Impact factor: 0.968

5.  Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China.

Authors:  Weier Wang; Jianming Tang; Fangqiang Wei
Journal:  J Med Virol       Date:  2020-02-12       Impact factor: 2.327

6.  Use of convalescent plasma therapy in SARS patients in Hong Kong.

Authors:  Y Cheng; R Wong; Y O Y Soo; W S Wong; C K Lee; M H L Ng; P Chan; K C Wong; C B Leung; G Cheng
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

7.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

  7 in total
  5 in total

Review 1.  Animal models for COVID-19: advances, gaps and perspectives.

Authors:  Changfa Fan; Yong Wu; Xiong Rui; Yuansong Yang; Chen Ling; Susu Liu; Shunan Liu; Youchun Wang
Journal:  Signal Transduct Target Ther       Date:  2022-07-07

Review 2.  Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.

Authors:  Alfredo Pennica; Giulia Conforti; Francesca Falangone; Antonio Martocchia; Laura Tafaro; Alberto Sentimentale; Valentina Marini; Aldo Pezzuto; Valerio Spuntarelli; Paolo Martelletti
Journal:  SN Compr Clin Med       Date:  2020-05-29

3.  Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease.

Authors:  Hadith Rastad; Hossein Karim; Hanieh-Sadat Ejtahed; Ramin Tajbakhsh; Mohammad Noorisepehr; Mehrdad Babaei; Mehdi Azimzadeh; Alireza Soleimani; Seyed Hasan Inanloo; Neda Shafiabadi Hassani; Fariba Rasanezhad; Ehsan Shahrestanaki; Zeinab Khodaparast; Hossein Golami; Mostafa Qorbani
Journal:  Diabetol Metab Syndr       Date:  2020-07-06       Impact factor: 3.320

4.  An unexpected and suspended time.

Authors:  Paolo Martelletti
Journal:  J Headache Pain       Date:  2020-04-22       Impact factor: 7.277

5.  Comparison of Computerized Prescription Support Systems in COVID-19 Patients: INTERCheck and Drug-PIN.

Authors:  Antonio Martocchia; Clara Bruscia; Giulia Conforti; Francesca Falangone; Valentina Marini; Alfredo Pennica; Aldo Pezzuto; Massimiliano Rocchietti March; Alberto Sentimentale; Valerio Spuntarelli; Laura Tafaro; Alberto Ricci; Maurizio Simmaco; Giorgio Sesti; Robert Preissner; Paolo Martelletti
Journal:  SN Compr Clin Med       Date:  2021-12-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.